Purpose of the development: Biosporin designed to prevent and treat dysbacterioses, acute diseases of the gastrointestinal tract of humans, pyogenic infections, chronic stomatitis.

Recommended application field: Medicine.

Advantages over analogues: Biosporin drug - highly effective drug on the basis of aerobic spore-forming bacteria. It is an association of microorganisms with high antagonistic activity against pathogenic and conditionally pathogenic microorganisms, does not affect the representatives of the normal microflora. The first domestic probiotic to treat people.

The development stage readiness: Introduced in production

Technical and economic effect: Patents of Ukraine and Russia. Analytical documentation. State registration of the drug.

Description of the development:
()
Biosporin refers to probiotics - preparations containing live microorganisms . As part Biosporin contains dried strains of aerobic saprophytes genus Bacillus: B. Subtilis and B. Licheniformis. These types of bacilli exhibit antagonistic activity against a number of pathogenic and conditionally pathogenic microorganisms selected . This activity is detected against bacteria of the genus Campylobacter, Proteus, Salmonella, Shigella, enteropathogenic E. Coli, Staphylococcus aureus , fungi of the genus Candida. The antagonistic properties of the products caused by the bacilli from the antibiotic properties of peptides and enzymes that enhance acidity , which also adversely affects the pathogenic species. The drug can suppress the livelihoods of antibiotic strains. Biosporin has a positive effect on the immune system : it stimulates the synthesis of immunoglobulins , activates macrophages , enhances the production of lysozyme and endogenous interferon . Biosporin helps improve intestinal absorption of vitamins K and E , as well as the normalization process of developing vitamin B bacillus belonging to the Biosporin not affect the microorganisms that normally inhabit the colon . Components of the drug is not absorbed from the intestinal lumen and thus do not enter the systemic circulation. Indications for use : - Intestinal infections caused by pathogens Salmonella, Shigella, enteropathogenic strains of E. Coli, Staphylococcus, Proteus, Campylobacter Candida, occurring in mild or moderate form (salmonellosis , dysentery, campylobacteriosis , food poisoning ); - The same infection occurring in severe form, in patients who have contraindications to antibiotics; - Period of convalescence after intestinal infections in the case of persistent carrier state ; - Dysbacteriosis caused prior antibiotic therapy or other causes ; - Bacterial vaginosis or vulvovaginal candidiasis (including during pregnancy) ; - Prevention of postoperative complications gnoynosepticheskih . Product: dried microbial mass in vials of 1 dose , № 10 . Composition: based on a single dose of lyophilised live cells B. Subtilis - 1-8 billion live cells of B. Licheniformis - 100 000 000 - 2 billion Other ingredients - gelatin, sucrose , sodium chloride .

Information about newness of the development:
there are Ukrainian patents -- 1 items
there are patents of other countries -- 1 items

corresponds technical description
Guarantees stable results getting

Possibility of transfer abroad:
Licence's sale
Licence's sale
Technological document's sale
Creation of joint enterprise
Realization of finished commodity

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua